EsoBiotec / AstraZeneca
AstraZeneca completed its acquisition in May 2025. ENaBL is a targeted lentiviral platform; anti-BCMA ESO-T01 has a published Phase 1 study in multiple myeloma. The small, uncontrolled study provides preliminary evidence, not established benefit.
Corporate information
- Company entity
- EsoBiotec / AstraZeneca
- Headquarters / principal office
- Mont-Saint-Guibert, BelgiumSelf-reported location on the company LinkedIn page; regional scope may differ from the legal or global headquarters. ↗
- Founded
- 2020 (company-reported) ↗
- Ownership / capital status
- AcquiredNot verified
- Official corporate reference
- https://www.astrazeneca.com/media-centre/press-releases/2025/acquisition-of-esobiotec-completed.html ↗
- LinkedIn company page
- LinkedIn ↗ ↗
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
AstraZeneca completed its acquisition in May 2025. ENaBL is a targeted lentiviral platform; anti-BCMA ESO-T01 has a published Phase 1 study in multiple myeloma. The small, uncontrolled study provides preliminary evidence, not established benefit.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- EsoBiotec / AstraZeneca — official page checked November 4, 2026
- EsoBiotec / AstraZeneca — supporting primary disclosure
- EsoBiotec company-managed LinkedIn location